MOR.DE - MorphoSys AG

XETRA - XETRA Delayed price. Currency in EUR
26.78
+1.30 (+5.10%)
At close: 05:35PM CEST
Stock chart is not supported by your current browser
Previous close25.48
Open25.62
Bid26.76 x 1500
Ask26.79 x 8800
Day's range25.57 - 27.10
52-week range11.81 - 27.10
Volume327,124
Avg. volume129,815
Market cap914.966M
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)-2.19
Earnings date01 Aug 2023 - 07 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est26.00
  • EQS Group

    MorphoSys AG Reports Outcome of Annual General Meeting 2023

    EQS-News: MorphoSys AG / Key word(s): AGM/EGMMorphoSys AG Reports Outcome of Annual General Meeting 2023 17.05.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 17, 2023 MorphoSys AG Reports Outcome of Annual General Meeting 2023All Proposed Resolutions ApprovedMorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Bo

  • Simply Wall St.

    With 47% ownership, MorphoSys AG (ETR:MOR) has piqued the interest of institutional investors

    Key Insights Institutions' substantial holdings in MorphoSys implies that they have significant influence over the...

  • EQS Group

    MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on

  • EQS Group

    MorphoSys AG Reports First Quarter 2023 Financial Results

    EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2023 Financial Results 03.05.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 03, 2023 MorphoSys AG Reports First Quarter 2023 Financial Results Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line mye

  • EQS Group

    Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023

    EQS-News: MorphoSys AG / Key word(s): Quarter ResultsInvitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023 27.04.2023 / 22:03 CET/CESTThe issuer is solely responsible for the content of this announcement.Conference Call AlertPlanegg/Munich, Germany, April 27, 2023 Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023

  • Simply Wall St.

    MorphoSys AG (ETR:MOR) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

    MorphoSys AG ( ETR:MOR ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. Not...

  • EQS Group

    MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Mo

  • Zacks

    MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

    As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

  • Motley Fool

    Why Shares of MorphoSys Are Up Wednesday

    Shares of MorphoSys (NASDAQ: MOR) were up more than 16% Wednesday afternoon after the biopharmaceutical company updated the trials status of the company's lead therapy. MorphoSys announced that its phase 3 combination study of pelabresib with ruxolitinib to treat myelofibrosis had completed its enrollment earlier than expected. Myelofibrosis is a blood cancer where there's a buildup of scar tissue in the bone marrow and can cause anemia and spleen enlargement.

  • EQS Group

    MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April 4, 2023 MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023Enrollment of Phase 3 frontMIND

  • EQS Group

    MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6) 24.03.2023 / 17:00 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), AUSTRALIA, SOUTH AFRICA,

  • EQS Group

    MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6) 23.03.2023 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), A

  • Simply Wall St.

    MorphoSys Full Year 2022 Earnings: Beats Expectations

    MorphoSys ( ETR:MOR ) Full Year 2022 Results Key Financial Results Revenue: €278.3m (up 55% from FY 2021). Net loss...

  • Business Wire

    MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    PLANEGG/MUNICH, Germany, March 15, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

  • EQS Group

    Lucinda Crabtree to Join MorphoSys as Chief Financial Officer

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousLucinda Crabtree to Join MorphoSys as Chief Financial Officer 14.03.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, March 14, 2023 Lucinda Crabtree to Join MorphoSys as Chief Financial OfficerMorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding

  • EQS Group

    Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023

    EQS-News: MorphoSys AG / Key word(s): Annual ResultsInvitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023 09.03.2023 / 22:03 CET/CESTThe issuer is solely responsible for the content of this announcement. Conference Call AlertPlanegg/Munich, Germany, March 9, 2023 Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08

  • Reuters

    Morphosys to slash early drug research programmes to preserve cash

    German biotech firm Morphosys said it would stop its work on drug candidates that have not yet been tested on humans after its 2023 revenue prospects worsened. In a statement on Thursday, Morphosys added it would reduce its workforce at the company’s headquarters in Planegg, Germany, by approximately 17% as a result of the cutback. Morphosys in January lowered its 2023 sales target for its most important drug, Monjuvi against a certain type of lymphoma, raising concerns among analysts about its ability to fund its research and development activities.

  • EQS Group

    MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Stops Work and Operations on Pre-Clinical Research Programs 02.03.2023 / 09:36 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release Planegg/Munich, Germany, March 2, 2023 MorphoSys Stops Work and Operations on Pre-Clinical Research Programs MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost

  • EQS Group

    Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters

    MorphoSys AG / Key word(s): MiscellaneousAd hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters02-March-2023 / 09:33 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publication of an inside information according to Article 17 para. 1 of the Regulatio

  • EQS Group

    MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

    EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MA

  • Simply Wall St.

    Investors in MorphoSys (ETR:MOR) have unfortunately lost 90% over the last three years

    As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...

  • EQS Group

    MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

    EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability 05.01.2023 / 11:38 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release Planegg/Munich, Germany, January 5, 2023 MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability Preliminary 2022 Monjuvi U.S. net prod

  • EQS Group

    Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

    MorphoSys AG / Key word(s): ForecastAd hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability05-Jan-2023 / 11:33 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publication of an inside information according to Article 17 para. 1 of the R

  • Reuters

    German pharma company MorphoSys's finance head to step down

    German pharma company MorphoSys said its finance chief Sung Lee would leave the company for personal reasons in March 2023 and that the company was seeking a successor to Sung, who joined in February 2021. The company suffered a major setback in November when an Alzheimer's drug candidate it was developing with Roche failed to slow the progress of the memory-robbing disease in two separate drug trials. "We understand Sung's desire to go back to California and the importance of his personal obligations," said company chair Marc Cluzel.

  • EQS Group

    Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023

    EQS-News: MorphoSys AG / Key word(s): MiscellaneousChief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, December 20, 2022 Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave Mo